Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

MYNZEPLI 40 mg/mL solution for injection in a vial {equilateral_black_triangle}

Discontinued
Active Ingredient:
ATC code: 
S01LA05
{info_black}
About Medicine
Mynzepli DME Patient Guide - Your guide to Mynzepli - for the treatment of visual impairment due to diabetic macular oedema (DME)

Mynzepli DME Patient Guide - Your guide to Mynzepli - for the treatment of visual impairment due to diabetic macular oedema (DME)


Mynzepli WAMD Patient Guide - Your guide to Mynzepli - for the treatment of neovascular (wet) age-related macular degeneration (AMD)

Mynzepli WAMD Patient Guide - Your guide to Mynzepli - for the treatment of neovascular (wet) age-related macular degeneration (AMD).


Mynzepli RVO Patient Guide - Your guide to Mynzepli - for the treatment of visual impairment due to retinal vein occlusion (RVO)

Mynzepli RVO Patient Guide - Your guide to Mynzepli - for the treatment of visual impairment due to retinal vein occlusion (RVO)


Mynzepli MCNV Patient Guide - Your guide to Mynzepli - for the treatment of visual impairment due to myopic choroidal neovascularisation (mCNV)

Mynzepli MCNV Patient Guide - Your guide to Mynzepli - for the treatment of visual impairment due to myopic choroidal neovascularisation (mCNV)


ADVANZ Pharma
Company image
Address
Dashwood House, 69 Old Broad Street, London, EC2M 1QS, UK
Telephone
+44 (0)208 588 9131
Medical Information Direct Line
+44 (0)208 588 9131
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)208 588 9273
Medical Information Website
https://medicalinformation.advanzpharma.com/